Literature DB >> 6424463

Synergy between acylureidopenicillins and immunoglobulin G in experimental animals.

A Dalhoff.   

Abstract

The interaction of a commercially available 7S modified immunoserumglobulin and beta-lactam antibiotics was studied in animal experiments (granuloma pouch model) as well as an ex vivo system (rat polyvinyl sponge model). Infections of the pouches were caused by gram-negative rods and gram-positive cocci, respectively. Therapy of pouches being infected with beta-lactamase-producing strains with beta-lactam antibiotics and immunoserumglobulin was as effective as beta-lactam antibiotic monotherapy of beta-lactamase-negative strains. This synergistic effect between immunoserumglobulin and beta-lactam antibiotics against beta-lactamase-producing bacteria is due to inactivation of enzymic beta-lactamase activity by specific antibodies against beta-lactamases. Immune phagocytosis was studied by adopting the in vivo and ex vivo models, respectively. Immune phagocytosis was most effectively stimulated by immunoserumglobulin whereas a pepsin-degraded product or a preparation obtained by pH4 treatment caused only minor effects. Furthermore, immunoserumglobulin stimulated phagocytosis and intracellular killing of gram-negative bacteria even in the absence of specific antibodies against these strains. Analogous effects were obtained with spermidine and albumin. These results indicate that immunoserumglobulin may stimulate phagocytosis nonspecifically, too. Thus, immunoserumglobulin may play a dual role in host defense mechanisms; in addition immunoserumglobulin acts as a beta-lactamase inhibitor, thus protecting beta-lactam antibiotics from hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424463     DOI: 10.1016/0002-9343(84)90326-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

Review 2.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice.

Authors:  A N Neely; I A Holder
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes.

Authors:  A Dalhoff
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

5.  Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials.

Authors:  G Pilz; S Kääb; G Neeser; I Class; U Schweigart; A Brähler; O Bujdoso; R Neumann; K Werdan
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

6.  Experimental Klebsiella septicemia in mice: treatment with specific antibodies from the rabbit alone and in combination with gentamicin.

Authors:  M Trautmann; Y Müller-Leutloff; T Hofstaetter; F R Seiler; H Hahn
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

7.  Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections.

Authors:  Nazir A Barekzi; Adrian G Felts; Kornelis A Poelstra; Jeffrey B Slunt; David W Grainger
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

8.  In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes.

Authors:  A Dalhoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 9.  Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology.

Authors:  Jody D Berry; Ryan G Gaudet
Journal:  N Biotechnol       Date:  2011-04-05       Impact factor: 5.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.